Skip to main content
Equibles
AYTU logo

AYTU · Aytu Biopharma, Inc · Webcasts, Transcripts & Audio

Track AYTU — free

Use AYTU with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AYTU.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.12 +0.05 (+2.17%)
Rebalance outlook locked
Market Cap
$23.91M
Shares
10.87M
Volume · Oct 5 49.11K Avg daily vol (3M) 35.06K

Aytu Biopharma, Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Aytu Biopharma, Inc (AYTU), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲26.3% $27.66M −$701,000 '23 Q1 22-11-14 ▲13.6% $26.28M −$6.69M '23 Q2 23-02-21 ▼6.1% $22.73M −$7.20M '23 Q3 23-05-11 ▲12% $30.73M −$2.46M '23 Q4 23-09-27 ▼35.6% $17.82M −$8.12M '24 Q1 23-11-14 ▼28.7% $18.75M −$220,000 '24 Q2 24-02-14 ▼38.3% $14.03M −$2.89M '24 Q3 24-05-15 ▼52.5% $14.59M −$4.62M '24 Q4 24-09-26 ▼7% $16.57M $1.47M '25 Q1 24-11-13 ▼13.5% $16.22M $788,000 '25 Q2 25-02-12 ▲31.6% $18.45M $3.99M '25 Q3 25-05-14 ▲3.7% $15.13M −$19.82M '25 Q4 25-09-23 ▼16.2% $13.89M $1.97M '26 Q1 25-11-13 ▼6.5% $15.16M −$10.58M '26 Q2 26-02-03 ▼32.7% $12.41M −$5.62M '26 Q3 26-05-13 LATEST ▲6.4% $16.11M −$15,000 '26 Q4 26-09-22
Earnings call
FY26 · Q4
2026-09-22
Aytu Biopharma, Inc (AYTU) Q4 2026 Earnings Call Transcript
Confident tone Exua (Actua) launch execution and prescription growth Financial performance and profitability path Methodical, ROI-driven commercial spending
Revenue
$16.11M*
▲ 6.4% YoY
Gross margin
64.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY26 · Q3
2026-05-13
Aytu Biopharma, Inc (AYTU) Q3 2026 Earnings Call Transcript
Confident tone Exua commercial launch momentum Prescription and unit growth metrics RxConnect patient access program
Revenue
$12.41M
▼ 32.7% YoY
Diluted EPS
$-0.53
▼ 352.4% YoY
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q2
2026-02-03
Aytu Biopharma, Inc (AYTU) Q2 2026 Earnings Call Transcript
Confident tone ExuA Launch (MDD) Patient / Consumer Demand Signals Mechanism / Clinical Differentiation
Revenue
$15.16M
▼ 6.5% YoY
Diluted EPS
$-1.05
Gross margin
63.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2025-11-13
Aytu Biopharma, Inc (AYTU) Q1 2026 Earnings Call Transcript
Confident tone EXXUA Launch ADHD Portfolio Aytu RxConnect Platform
Revenue
$13.89M
▼ 16.2% YoY
Diluted EPS
$-0.08
Gross margin
66.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2025-09-23
Aytu Biopharma, Inc (AYTU) Q4 2025 Earnings Call Transcript
Confident tone ExuA Launch and Market Opportunity ADHD and Pediatric Portfolio Competitive Differentiation vs SSRIs/SNRIs
Revenue
$15.13M*
▲ 3.7% YoY
Gross margin
67.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-05-14
Aytu Biopharma, Inc (AYTU) Q3 2025 Earnings Call Transcript
Confident tone ADHD Portfolio Growth Pediatric Portfolio Turnaround Aytu RxConnect Platform
Revenue
$18.45M
▲ 31.6% YoY
Diluted EPS
$0.21
Gross margin
69.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-02-12
Aytu Biopharma, Inc (AYTU) Q2 2025 Earnings Call Transcript
Confident tone ADHD Portfolio Growth Cost Optimization & EBITDA Aytu RxConnect Platform
Revenue
$16.22M
▼ 13.5% YoY
Diluted EPS
$-0.26
Gross margin
66.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2024-11-13
Aytu Biopharma, Inc (AYTU) Q1 2025 Earnings Call Transcript
Confident tone Profitability Milestones Organizational Restructuring & Cost Reduction Pediatric Portfolio
Revenue
$16.57M
▼ 7% YoY
Diluted EPS
$-0.15
Gross margin
72.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-09-26
Aytu Biopharma, Inc (AYTU) Q4 2024 Earnings Call Transcript
Confident tone Pediatric products recovery (Karbinal ER, multivitamins) ADHD portfolio growth Repositioning as specialty prescription pharma
Revenue
$14.59M*
▼ 52.5% YoY
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-05-15
Aytu Biopharma, Inc (AYTU) Q3 2024 Earnings Call Transcript
Confident tone ADHD Portfolio Growth Pediatric Portfolio Fiscal 2025 Outlook and Re-rating
Revenue
$14.03M
▼ 38.3% YoY
Diluted EPS
$-0.52
Gross margin
73.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-02-14
Aytu Biopharma, Inc (AYTU) Q2 2024 Earnings Call Transcript
Confident tone Financial Milestones and Profitability ADHD Portfolio Growth VYVANSE Generic Disruption Opportunity
Revenue
$18.75M
▼ 28.7% YoY
Diluted EPS
$-0.04
Gross margin
77.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2023-11-14
Aytu Biopharma, Inc (AYTU) Q1 2024 Earnings Call Transcript
Revenue
$17.82M
▼ 35.6% YoY
Diluted EPS
$-1.48
Gross margin
73.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-09-27
Aytu Biopharma, Inc (AYTU) Q4 2023 Earnings Call Transcript
Revenue
$30.73M*
▲ 12% YoY
Gross margin
60.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-05-11
Aytu Biopharma, Inc (AYTU) Q3 2023 Earnings Call Transcript
Revenue
$22.73M
▼ 6.1% YoY
Diluted EPS
$-1.93
Gross margin
56.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-02-21
Aytu Biopharma, Inc (AYTU) Q2 2023 Earnings Call Transcript
Revenue
$26.28M
▲ 13.6% YoY
Diluted EPS
$-2.15
Gross margin
65.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2022-11-14
Aytu Biopharma, Inc (AYTU) Q1 2023 Earnings Call Transcript
Revenue
$27.66M
▲ 26.3% YoY
Diluted EPS
$-0.28
Gross margin
65.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2022-09-28
Aytu Biopharma, Inc (AYTU) Q4 2022 Earnings Call Transcript
Revenue
$27.45M*
▲ 16.9% YoY
Gross margin
54.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q2
2022-02-14
Aytu Biopharma, Inc (AYTU) Q2 2022 Earnings Call
Revenue
$23.12M
▲ 52.7% YoY
Diluted EPS
$-8.74
Gross margin
53.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2021-11-15
Aytu Biopharma, Inc (AYTU) Q1 2022 Earnings Call Transcript
Revenue
$21.90M
▲ 62% YoY
Diluted EPS
$-21.76
Gross margin
56.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-09-27
Aytu Biopharma, Inc (AYTU) Q4 2021 Earnings Call
Revenue
$23.48M*
▲ 58% YoY
Gross margin
48.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-05-17
Aytu Biopharma, Inc (AYTU) Q3 2021 Earnings Call
Revenue
$13.48M
▲ 65.3% YoY
Diluted EPS
$-28.20
Gross margin
-3.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-02-11
Aytu Biopharma, Inc (AYTU) Q2 2021 Earnings Call
Revenue
$15.15M
▲ 377.1% YoY
Diluted EPS
$-14.40
Gross margin
58.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2020-10-06
Aytu Biopharma, Inc (AYTU) Q1 2021 Earnings Call
Revenue
$13.52M
▲ 839% YoY
Diluted EPS
$-7.00
Gross margin
69.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q3
2020-05-14
Aytu Biopharma, Inc (AYTU) Q3 2020 Earnings Call Transcript
Revenue
$8.16M
▲ 243% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-02-13
Aytu Biopharma, Inc (AYTU) Q2 2020 Earnings Call Transcript
Revenue
$3.17M
▲ 76.9% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2019-09-30
Aytu Biopharma, Inc (AYTU) Q1 2020 Earnings Call Transcript
Revenue
$1.44M
▲ 0.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–26 of 26 webcasts
Key facts CIK 1385818 CUSIP 054754858 Visit website Investor relations